Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
Identifieur interne : 001F04 ( Pmc/Curation ); précédent : 001F03; suivant : 001F05Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
Auteurs : Yasmin A. Lyons [États-Unis] ; Michael Frumovitz [États-Unis] ; Pamela T. Soliman [États-Unis]Source :
- Gynecologic Oncology Reports [ 2352-5789 ] ; 2014.
Abstract
Molecular testing may play a role in the determination of targeted therapy treatment options. Targeted therapy provides treatment options for recurrent cervical cancer. MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.
Url:
DOI: 10.1016/j.gore.2014.09.003
PubMed: 26075998
PubMed Central: 4434143
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F05
Links to Exploration step
PMC:4434143Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation</title><author><name sortKey="Lyons, Yasmin A" sort="Lyons, Yasmin A" uniqKey="Lyons Y" first="Yasmin A." last="Lyons">Yasmin A. Lyons</name><affiliation wicri:level="1"><nlm:aff id="af0005">Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, United States</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Frumovitz, Michael" sort="Frumovitz, Michael" uniqKey="Frumovitz M" first="Michael" last="Frumovitz">Michael Frumovitz</name><affiliation wicri:level="1"><nlm:aff id="af0010">Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Soliman, Pamela T" sort="Soliman, Pamela T" uniqKey="Soliman P" first="Pamela T." last="Soliman">Pamela T. Soliman</name><affiliation wicri:level="1"><nlm:aff id="af0010">Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26075998</idno><idno type="pmc">4434143</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434143</idno><idno type="RBID">PMC:4434143</idno><idno type="doi">10.1016/j.gore.2014.09.003</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001F05</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001F05</idno><idno type="wicri:Area/Pmc/Curation">001F04</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001F04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation</title><author><name sortKey="Lyons, Yasmin A" sort="Lyons, Yasmin A" uniqKey="Lyons Y" first="Yasmin A." last="Lyons">Yasmin A. Lyons</name><affiliation wicri:level="1"><nlm:aff id="af0005">Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, United States</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Frumovitz, Michael" sort="Frumovitz, Michael" uniqKey="Frumovitz M" first="Michael" last="Frumovitz">Michael Frumovitz</name><affiliation wicri:level="1"><nlm:aff id="af0010">Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Soliman, Pamela T" sort="Soliman, Pamela T" uniqKey="Soliman P" first="Pamela T." last="Soliman">Pamela T. Soliman</name><affiliation wicri:level="1"><nlm:aff id="af0010">Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author></analytic><series><title level="j">Gynecologic Oncology Reports</title><idno type="eISSN">2352-5789</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Highlights</title><p><list list-type="simple"><list-item id="u0005"><label>•</label><p>Molecular testing may play a role in the determination of targeted therapy treatment options.</p></list-item><list-item id="u0010"><label>•</label><p>Targeted therapy provides treatment options for recurrent cervical cancer.</p></list-item><list-item id="u0015"><label>•</label><p>MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.</p></list-item></list></p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Chan, J K" uniqKey="Chan J">J.K. Chan</name></author><author><name sortKey="Loizzi, V" uniqKey="Loizzi V">V. Loizzi</name></author><author><name sortKey="Burger, R A" uniqKey="Burger R">R.A. Burger</name></author><author><name sortKey="Rutgers, J" uniqKey="Rutgers J">J. Rutgers</name></author><author><name sortKey="Monk, B J" uniqKey="Monk B">B.J. Monk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koch, C A" uniqKey="Koch C">C.A. Koch</name></author><author><name sortKey="Gimm, O" uniqKey="Gimm O">O. Gimm</name></author><author><name sortKey="Vortmeyer, A O" uniqKey="Vortmeyer A">A.O. Vortmeyer</name></author><author><name sortKey="Al Ali, H K" uniqKey="Al Ali H">H.K. Al-Ali</name></author><author><name sortKey="Lamesch, P" uniqKey="Lamesch P">P. Lamesch</name></author><author><name sortKey="Ott, R" uniqKey="Ott R">R. Ott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, P" uniqKey="Zhang P">P. Zhang</name></author><author><name sortKey="Gao, W" uniqKey="Gao W">W. Gao</name></author><author><name sortKey="Turner, S" uniqKey="Turner S">S. Turner</name></author><author><name sortKey="Ducatman, B S" uniqKey="Ducatman B">B.S. Ducatman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wee, S" uniqKey="Wee S">S. Wee</name></author><author><name sortKey="Jagani, Z" uniqKey="Jagani Z">Z. Jagani</name></author><author><name sortKey="Xiang, K X" uniqKey="Xiang K">K.X. Xiang</name></author><author><name sortKey="Loo, A" uniqKey="Loo A">A. Loo</name></author><author><name sortKey="Dorsch, M" uniqKey="Dorsch M">M. Dorsch</name></author><author><name sortKey="Yao, Y M" uniqKey="Yao Y">Y.M. Yao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, K L" uniqKey="Wang K">K.L. Wang</name></author><author><name sortKey="Chang, T C" uniqKey="Chang T">T.C. Chang</name></author><author><name sortKey="Jung, S M" uniqKey="Jung S">S.M. Jung</name></author><author><name sortKey="Chen, C H" uniqKey="Chen C">C.H. Chen</name></author><author><name sortKey="Cheng, Y M" uniqKey="Cheng Y">Y.M. Cheng</name></author><author><name sortKey="Wu, H H" uniqKey="Wu H">H.H. Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zivanovich, O" uniqKey="Zivanovich O">O. Zivanovich</name></author><author><name sortKey="Leitao, M M" uniqKey="Leitao M">M.M. Leitao</name></author><author><name sortKey="Park, K J" uniqKey="Park K">K.J. Park</name></author><author><name sortKey="Diaz, J P" uniqKey="Diaz J">J.P. Diaz</name></author><author><name sortKey="Konner, J" uniqKey="Konner J">J. Konner</name></author><author><name sortKey="Alektiar, K" uniqKey="Alektiar K">K. Alektiar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, S W" uniqKey="Lee S">S.W. Lee</name></author><author><name sortKey="Nam, J H" uniqKey="Nam J">J.H. Nam</name></author><author><name sortKey="Kim, D Y" uniqKey="Kim D">D.Y. Kim</name></author><author><name sortKey="Kim, J H" uniqKey="Kim J">J.H. Kim</name></author><author><name sortKey="Kim, K R" uniqKey="Kim K">K.R. Kim</name></author><author><name sortKey="Kim, Y M" uniqKey="Kim Y">Y.M. Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wright, A A" uniqKey="Wright A">A.A. Wright</name></author><author><name sortKey="Howitt, B E" uniqKey="Howitt B">B.E. Howitt</name></author><author><name sortKey="Myers, A P" uniqKey="Myers A">A.P. Myers</name></author><author><name sortKey="Dahlberg, S E" uniqKey="Dahlberg S">S.E. Dahlberg</name></author><author><name sortKey="Palescandolo, E P" uniqKey="Palescandolo E">E.P. Palescandolo</name></author><author><name sortKey="Hummelen, P V" uniqKey="Hummelen P">P.V. Hummelen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rinehart, J" uniqKey="Rinehart J">J. Rinehart</name></author><author><name sortKey="Adjei, A A" uniqKey="Adjei A">A.A. Adjei</name></author><author><name sortKey="Lorusso, P M" uniqKey="Lorusso P">P.M. LoRusso</name></author><author><name sortKey="Waterhouse, D" uniqKey="Waterhouse D">D. Waterhouse</name></author><author><name sortKey="Hecht, J R" uniqKey="Hecht J">J.R. Hecht</name></author><author><name sortKey="Natale, R B" uniqKey="Natale R">R.B. Natale</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="brief-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Gynecol Oncol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Gynecol Oncol Rep</journal-id><journal-title-group><journal-title>Gynecologic Oncology Reports</journal-title></journal-title-group><issn pub-type="epub">2352-5789</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26075998</article-id><article-id pub-id-type="pmc">4434143</article-id><article-id pub-id-type="publisher-id">S2352-5789(14)00034-4</article-id><article-id pub-id-type="doi">10.1016/j.gore.2014.09.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lyons</surname><given-names>Yasmin A.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Frumovitz</surname><given-names>Michael</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Soliman</surname><given-names>Pamela T.</given-names></name><email>psoliman@mdanderson.org</email><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, United States</aff><aff id="af0010"><label>b</label>Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States</aff><author-notes><corresp id="cr0005"><label>⁎</label>Corresponding author at: Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Drive, P.O. Box 301439, Unit 1362, Houston, TX 77030, United States. Fax: + 1 713 792 7586. <email>psoliman@mdanderson.org</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>10</month><year>2014</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="collection"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>10</month><year>2014</year></pub-date><volume>10</volume><fpage>28</fpage><lpage>29</lpage><history><date date-type="received"><day>16</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>18</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Authors</copyright-statement><copyright-year>2014</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).</license-p></license></permissions><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="u0005"><label>•</label><p>Molecular testing may play a role in the determination of targeted therapy treatment options.</p></list-item><list-item id="u0010"><label>•</label><p>Targeted therapy provides treatment options for recurrent cervical cancer.</p></list-item><list-item id="u0015"><label>•</label><p>MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.</p></list-item></list></p></abstract><kwd-group><title>Keywords</title><kwd>Small cell neuroendocrine carcinoma</kwd><kwd>KRAS mutation</kwd><kwd>MEK inhibitor</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001F04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4434143
|texte= Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:26075998" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |